A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.
about
Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control studyA double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats.Early monitoring for detection of antituberculous drug-induced hepatotoxicityThe clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens.Generation of proliferating human hepatocytes using Upcyte® technology: characterisation and applications in induction and cytotoxicity assays.Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study.Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.
P2860
Q28488142-113CBAC1-4F74-424F-9EA6-7A8AD55A067AQ35786010-92B7C507-0EE5-48D3-9B28-0A822CD824B1Q36058879-10ABA46E-2F86-4101-B5F8-A18116381308Q36364005-88D56EE3-1D8C-4AAB-B2FB-C98BE051DCF8Q36428771-46E6CA8B-D886-407D-AD8C-1D3D193F935EQ36461154-A46189BC-3B38-4028-9F42-A31F67B2CE18Q36697119-B0CA6BBD-2451-439C-9C70-1496B06D6845Q38220765-478A2854-9EF2-4CC5-9B8F-5907E3C072CFQ40096207-D1B5E273-3376-4BC2-8019-E50A775CD2E4Q41684440-464BEDC7-05F9-4EA3-9E6F-F43468410231Q42505249-FF3D58A6-1744-4FC8-A66C-77F37262D6E6Q51542639-7CCA5E4D-5AD2-424E-8D9E-069C4C619D82Q54980590-C70A1D9E-3871-4F53-9C05-332AD1DB846C
P2860
A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A prospective study of antitub ...... ea endemic for liver diseases.
@en
A prospective study of antitub ...... ea endemic for liver diseases.
@nl
type
label
A prospective study of antitub ...... ea endemic for liver diseases.
@en
A prospective study of antitub ...... ea endemic for liver diseases.
@nl
prefLabel
A prospective study of antitub ...... ea endemic for liver diseases.
@en
A prospective study of antitub ...... ea endemic for liver diseases.
@nl
P2093
P2860
P1476
A prospective study of antitub ...... ea endemic for liver diseases.
@en
P2093
Ahmed Helmy
Ehab Fawzy
Hebat Alla G Rashed
Hoda A Makhlouf
Madiha El-Attar
P2860
P2888
P304
P356
10.1007/S12072-008-9085-Y
P577
2008-07-25T00:00:00Z